Orbimed Advisors LLC
Orbimed Advisors LLC reported 117 US-listed holdings worth $5.27 billion in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Edgewise Therapeutics Inc. (12.0%), Enliven Therapeutics Inc. (6.5%) and Eli Lilly & Co. (5.9%). Against the quarter before, it opened 32 positions, added to 32, trimmed 26 and sold out of 20.
Reported holdings$5.27B+19.1% on Q1 2026
Positions117+12 on Q1 2026
The largest ten43.1%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
Added toHeldTrimmed
The 14 largest of its 117 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What it did on the quarter
Opened 32Added 32Held 27Trimmed 26Sold out 20
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 32
- UnitedHealth Group Inc. UNH$67.0 million
- Ascendis Pharma A/s ASND$65.2 million
- Humana Inc. HUM$65.2 million
- Odyssey Therapeutics, Inc. ODTX$56.2 million
- Arcutis Biotherapeutics Inc. ARQT$53.5 million
- West Pharmaceutical Services Inc. WST$25.3 million
- Aura Biosciences Inc. AURA$23.7 million
- Spyre Therapeutics Inc. SYRE$16.5 million
and 24 more in the table below
Added to 32
- Cogent Biosciences Inc. COGT+1.4 million shares · +422%
- AstraZeneca PLC AZN+245,500 shares · +37%
- Structure Therapeutics Inc. GPCR+733,997 shares · +50%
- Eli Lilly & Co. LLY+21,100 shares · +9%
- Palvella Therapeutics Inc. Ne PVLA+157,760 shares · +117%
- Q32 Bio Inc. QTTB+1.9 million shares · +83%
- Guardant Health Inc. GH+148,500 shares · +34%
- Thermo Fisher Scientific Inc. TMO+44,200 shares · +95%
and 24 more in the table below
Trimmed 26
- Enliven Therapeutics Inc. ELVN-1.2 million shares · -15%
- Disc Medicine Inc. IRON-710,015 shares · -67%
- Sionna Therapeutics Inc SION-974,825 shares · -28%
- argenx SE ARGX-44,020 shares · -32%
- Boston Scientific Corp. BSX-898,900 shares · -38%
- Edwards Lifesciences Corp. EW-395,700 shares · -32%
- Alnylam Pharmaceuticals Inc ALNY-102,000 shares · -86%
- Axsome Therapeutics Inc. AXSM-96,343 shares · -45%
and 18 more in the table below
Sold out of 20
- Pfizer Inc. PFE$54.7 million last quarter
- Danaher Corp. DHR$50.4 million last quarter
- Ascendis Pharma A/s ASND$41.6 million last quarter
- Esperion Therapeutics Inc. Ne ESPR$29.0 million last quarter
- BrightSpring Health Services, Inc. BTSG$21.2 million last quarter
- Amgen Inc. AMGN$14.0 million last quarter
- Alignment Healthcare, Inc. ALHC$13.9 million last quarter
- Regeneron Pharmaceuticals, Inc. REGN$11.4 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Edgewise Therapeutics Inc. EWTX | 15,518,492 | $630.5 million | 11.97% | no change |
| Enliven Therapeutics Inc. ELVN | 6,776,632 | $343.9 million | 6.53% | -1,182,906 |
| Eli Lilly & Co. LLY | 257,900 | $309.3 million | 5.87% | +21,100 |
| MBX Biosciences Inc. MBX | 3,428,736 | $189.3 million | 3.59% | -209,151 |
| Sinovac Biotech Ltd | 2,718,735 | $184.5 million | 3.50% | no change |
| AstraZeneca PLC AZN | 915,700 | $171.1 million | 3.25% | +245,500 |
| Structure Therapeutics Inc. GPCR | 2,209,400 | $118.6 million | 2.25% | +733,997 |
| Sionna Therapeutics Inc SION | 2,555,877 | $112.4 million | 2.13% | -974,825 |
| Corvus Pharmaceuticals Inc. CRVS | 7,165,006 | $107.0 million | 2.03% | no change |
| Arrivent Biopharma Inc. AVBP | 3,027,328 | $105.2 million | 2.00% | no change |
| Guardant Health Inc. GH | 583,700 | $87.6 million | 1.66% | +148,500 |
| argenx SE ARGX | 92,880 | $86.2 million | 1.64% | -44,020 |
| Merck & Co., Inc. MRK | 663,400 | $85.2 million | 1.62% | no change |
| Uniqure NV QURE | 1,807,486 | $83.3 million | 1.58% | -328,663 |
| Praxis Precision Medicines I PRAX | 230,100 | $77.0 million | 1.46% | +57,600 |
| Edwards Lifesciences Corp. EW | 834,900 | $75.5 million | 1.43% | -395,700 |
| Prelude Therapeutics Inc. PRLD | 13,724,571 | $73.2 million | 1.39% | +2,815,315 |
| Abivax SA ABVX | 546,522 | $72.8 million | 1.38% | +80,822 |
| Dyne Therapeutics Inc. DYN | 3,235,684 | $71.9 million | 1.36% | +317,800 |
| Natera Inc Com NTRA | 262,000 | $71.1 million | 1.35% | no change |
| CG Oncology Inc. CGON | 972,800 | $69.1 million | 1.31% | +24,533 |
| UnitedHealth Group Inc. UNH | 161,100 | $67.0 million | 1.27% | new |
| Ars Pharmaceuticals Inc. SPRY | 8,288,510 | $66.4 million | 1.26% | no change |
| Ascendis Pharma A/s ASND | 244,456 | $65.2 million | 1.24% | new |
| Humana Inc. HUM | 164,100 | $65.2 million | 1.24% | new |
| Cogent Biosciences Inc. COGT | 1,681,300 | $65.1 million | 1.24% | +1,359,200 |
| Boston Scientific Corp. BSX | 1,483,200 | $63.3 million | 1.20% | -898,900 |
| Intuitive Surgical Inc. ISRG | 157,900 | $62.8 million | 1.19% | -50,800 |
| Mineralys Therapeutics Inc. MLYS | 2,110,300 | $56.9 million | 1.08% | +57,400 |
| Odyssey Therapeutics, Inc. ODTX | 3,001,198 | $56.2 million | 1.07% | new |
| Xenon Pharmaceuticals Inc. XENE | 892,471 | $53.9 million | 1.02% | -167,500 |
| Arcutis Biotherapeutics Inc. ARQT | 2,042,000 | $53.5 million | 1.02% | new |
| Bristol-Myers Squibb Co. BMY | 925,000 | $53.3 million | 1.01% | no change |
| Q32 Bio Inc. QTTB | 4,127,987 | $52.6 million | 1.00% | +1,875,000 |
| Stryker Corp. SYK | 159,100 | $50.1 million | 0.95% | -23,400 |
| Caris Life Sciences Inc. CAI | 2,806,811 | $50.0 million | 0.95% | no change |
| Thermo Fisher Scientific Inc. TMO | 90,700 | $45.5 million | 0.86% | +44,200 |
| Palvella Therapeutics Inc. Ne PVLA | 292,360 | $44.7 million | 0.85% | +157,760 |
| Elevance Health, Inc. ELV | 114,700 | $44.4 million | 0.84% | no change |
| Shattuck Labs Inc. STTK | 6,306,127 | $43.8 million | 0.83% | no change |
| Upstream Bio Inc. UPB | 5,693,589 | $39.4 million | 0.75% | no change |
| Crinetics Pharmaceuticals in CRNX | 999,000 | $37.4 million | 0.71% | no change |
| Rhythm Pharmaceuticals Inc. RYTM | 322,900 | $35.9 million | 0.68% | +8,800 |
| Syndax Pharmaceuticals Inc. SNDX | 1,542,000 | $33.7 million | 0.64% | +579,700 |
| Forte Biosciences Inc. FBRX | 1,577,705 | $33.5 million | 0.64% | +380,750 |
| Compass Therapeutics Inc. CMPX | 15,219,994 | $33.3 million | 0.63% | no change |
| Nektar Therapeutics NKTR | 465,346 | $32.5 million | 0.62% | +190,346 |
| Krystal Biotech, Inc. KRYS | 83,200 | $30.9 million | 0.59% | +14,100 |
| NA | 5,680,186 | $30.3 million | 0.57% | -530,713 |
| Axsome Therapeutics Inc. AXSM | 117,578 | $28.8 million | 0.55% | -96,343 |
| Kiniksa Pharmaceuticals Intl KNSA | 420,600 | $26.9 million | 0.51% | +240,001 |
| Trevi Therapeutics Inc. TRVI | 1,430,293 | $26.7 million | 0.51% | -1,024,107 |
| Disc Medicine Inc. IRON | 357,535 | $26.2 million | 0.50% | -710,015 |
| West Pharmaceutical Services Inc. WST | 70,600 | $25.3 million | 0.48% | new |
| Relmada Therapeutics Inc. RLMD | 3,631,195 | $25.1 million | 0.48% | -1,084,669 |
| Urogen Pharma Ltd URGN | 676,187 | $24.9 million | 0.47% | -199,300 |
| Sutro Biopharma Inc. STRO | 743,944 | $24.7 million | 0.47% | -57,200 |
| Savara Inc. SVRA | 3,959,900 | $24.4 million | 0.46% | +3,324,900 |
| Neuropace Inc. NPCE | 1,505,125 | $23.9 million | 0.45% | -591,402 |
| Aura Biosciences Inc. AURA | 3,333,333 | $23.7 million | 0.45% | new |
| Oric Pharmaceuticals Inc. ORIC | 2,015,000 | $21.8 million | 0.41% | -678,929 |
| Cybin Inc. HELP | 3,271,400 | $21.6 million | 0.41% | -561,443 |
| Biocryst Pharmaceuticals Inc. BCRX | 1,852,000 | $18.5 million | 0.35% | +426,800 |
| Bioage Labs Inc. BIOA | 752,153 | $18.4 million | 0.35% | +40,342 |
| Lexeo Therapeutics Inc. LXEO | 3,947,850 | $18.4 million | 0.35% | +345,400 |
| Aadi Bioscience Inc. WHWK | 3,934,296 | $18.0 million | 0.34% | -231,704 |
| Definium Therapeutics Inc. DFTX | 365,400 | $17.2 million | 0.33% | -438,600 |
| Spyre Therapeutics Inc. SYRE | 186,145 | $16.5 million | 0.31% | new |
| Corbus Pharmaceuticals Hldgs CRBP | 1,737,287 | $16.3 million | 0.31% | no change |
| Vera Therapeutics Inc. VERA | 369,596 | $15.9 million | 0.30% | no change |
| Alumis Inc. ALMS | 548,163 | $15.4 million | 0.29% | no change |
| Eyepoint Pharmaceuticals Inc. EYPT | 1,069,147 | $15.3 million | 0.29% | no change |
| Waters Corp. WAT | 40,300 | $15.1 million | 0.29% | new |
| Monopar Therapeutics Inc. MNPR | 157,423 | $14.6 million | 0.28% | new |
| Travere Therapeutics Inc. TVTX | 253,000 | $14.4 million | 0.27% | new |
| Taysha Gene Therapies Inc. TSHA | 2,000,000 | $13.6 million | 0.26% | new |
| Biogen Inc. BIIB | 61,600 | $13.3 million | 0.25% | no change |
| Revolution Medicines, Inc. RVMD | 70,500 | $13.2 million | 0.25% | +18,500 |
| Dianthus Therapeutics Inc. DNTH | 115,000 | $11.2 million | 0.21% | new |
| Spruce Biosciences Inc. SPRB | 200,000 | $10.8 million | 0.21% | new |
| LifeStance Health Group, Inc. LFST | 947,400 | $10.1 million | 0.19% | +447,400 |
| Erasca Inc. ERAS | 495,900 | $9.1 million | 0.17% | new |
| Protara Therapeutics Inc. TARA | 2,220,000 | $8.5 million | 0.16% | new |
| Keros Therapeutics Inc. KROS | 759,155 | $8.1 million | 0.15% | no change |
| Janux Therapeutics Inc. JANX | 524,700 | $8.1 million | 0.15% | -458,900 |
| Tectonic Therapeutic Inc. TECX | 226,600 | $7.8 million | 0.15% | no change |
| Adicet Bio Inc. ACET | 844,787 | $7.3 million | 0.14% | -183,157 |
| Pharvaris N V PHVS | 205,400 | $7.1 million | 0.13% | no change |
| Alto Neuroscience Inc. ANRO | 257,852 | $6.8 million | 0.13% | +90,352 |
| Zentalis Pharmaceuticals Inc. ZNTL | 1,390,576 | $6.7 million | 0.13% | new |
| Bright Minds Biosciences Inc. DRUG | 93,000 | $6.5 million | 0.12% | +53,000 |
| Alx Oncology Holdings Inc. ALXO | 2,866,256 | $5.9 million | 0.11% | no change |
| Xilio Therapeutics Inc. XLO | 592,300 | $5.7 million | 0.11% | new |
| Bicara Therapeutics Inc. BCAX | 191,100 | $5.7 million | 0.11% | -476,200 |
| Imagenebio Inc. IMA | 909,269 | $5.4 million | 0.10% | +530,713 |
| Protagonist Therapeutics, Inc. PTGX | 42,100 | $5.2 million | 0.10% | no change |
| Alnylam Pharmaceuticals Inc ALNY | 17,000 | $5.1 million | 0.10% | -102,000 |
| Palisade Bio Inc. PALI | 2,333,000 | $4.9 million | 0.09% | no change |
| Atai Beckley NV ATAI | 797,500 | $4.2 million | 0.08% | +450,500 |
| PTC Therapeutics, Inc. PTCT | 49,100 | $4.0 million | 0.08% | no change |
| Artivion, Inc. AORT | 175,000 | $3.9 million | 0.07% | +24,000 |
| Neumora Therapeutics Inc. NMRA | 2,139,882 | $3.6 million | 0.07% | new |
| Acadia Pharmaceuticals Inc. ACAD | 137,000 | $3.5 million | 0.07% | new |
| Amylyx Pharmaceuticals Inc. AMLX | 183,400 | $3.3 million | 0.06% | new |
| Tyra Biosciences Inc. TYRA | 102,000 | $3.3 million | 0.06% | new |
| Rapport Therapeutics Inc. RAPP | 76,616 | $3.2 million | 0.06% | new |
| Agomab Therapeutics NV AGMB | 192,740 | $2.5 million | 0.05% | new |
| Tarsus Pharmaceuticals Inc. TARS | 35,581 | $2.2 million | 0.04% | new |
| Aclaris Therapeutics Inc. ACRS | 421,500 | $2.2 million | 0.04% | new |
| Cytokinetics Inc. CYTK | 25,800 | $2.2 million | 0.04% | new |
| Inspiremd Inc. NSPR | 3,133,405 | $2.2 million | 0.04% | no change |
| Ocular Therapeutix Inc. OCUL | 220,000 | $2.2 million | 0.04% | new |
| Evommune Inc. EVMN | 161,000 | $2.1 million | 0.04% | new |
| Belite Bio Inc. BLTE | 13,300 | $2.0 million | 0.04% | new |
| Ovid Therapeutics Inc. OVID | 747,000 | $2.0 million | 0.04% | new |
| Eupraxia Pharmaceuticals Inc. EPRX | 269,000 | $1.8 million | 0.03% | new |
| Traws Pharma Inc. TRAW | 1,203,260 | $1.0 million | 0.02% | +597,729 |
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read more
Change is shares against its 13F for the quarter before; the 20 it sold out of are in the box above.Options it reported
| Company | Option | Shares under the options | Value of those shares |
|---|---|---|---|
| SPDR Ser Trust XBI | Puts | 300,000 | $47.5 million |
| Abivax SA ABVX | Calls | 200,000 | $26.7 million |
| Protagonist Therapeutics, Inc. PTGX | Calls | 150,000 | $18.4 million |
| Revolution Medicines, Inc. RVMD | Calls | 50,000 | $9.4 million |
| Palvella Therapeutics Inc. Ne PVLA | Calls | 40,000 | $6.1 million |
| UnitedHealth Group Inc. UNH | Calls | 10,000 | $4.2 million |
| Elevance Health, Inc. ELV | Calls | 10,000 | $3.9 million |
| Sellas Life Sciences Group I SLS | Puts | 92,500 | $1.4 million |
8 option lines. A 13F lists calls and puts by the shares they cover and what those shares were worth at the quarter's end, not what the options cost; they are not counted in the holdings above.